Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Saved in:
| Title: | Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). |
|---|---|
| Authors: | Holch, J.W.1,2 Julian.Holch@med.uni-muenchen.de, Ricard, I.3, Stintzing, S.1,2, Fischer von Weikersthal, L.4, Decker, T.5, Kiani, A.6, Vehling-Kaiser, U.7, Heintges, T.8, Kahl, C.9, Kullmann, F.10, Scheithauer, W.11, Moehler, M.12, Jelas, I.1,2, Modest, D.P.1,2, Westphalen, C.B.1,2, von Einem, J.C.1,2, Michl, M.1,2, Heinemann, V.1,2 |
| Source: | European Journal of Cancer. Jan2019, Vol. 106, p115-125. 11p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
